Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Grail

Illumina Surges As Activist Investor Carl Icahn Attempts To Wrest Control

Activist investor Carl Icahn is fighting for control of Illumina after the acquisition of Grail. In response, ILMN stock surged Monday.

Investors Business Daily

Illumina's Woes Mount As Guidance Lags And Grail Controversy Continues

Illumina stock plunged to its lowest point in three months Tuesday after the gene-sequencing giant issued a disappointing outlook for 2023.

Investors Business Daily

A frozen capital market and an insurance premium shock: 10 health care predictions for 2023 from top investors

Distressed deals, inflation in insurance premiums, and restrictions on transgender treatments. Here's what the health care sector will look like in 2023, according to top investors.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

A blood test that screens for multiple cancers at once promises to boost early detection

Detecting cancer early before it spreads throughout the body can be lifesaving. This is why doctors recommend regular screening for several common cancer types, using a variety of methods. Colonoscopies, for example, screen for colon cancer, while mammograms screen for breast cancer.

The Conversation

Faye Flam: Better cancer screenings are coming. Can we afford them?

Patients and their doctors count on cancer screening tests to save lives, and yet a number of large, controlled studies are showing disappointing results for mammography and other mass screening tests. This month, the New England Journal of Medicine published a controversial study that cast doubt on the widely accepted…

Tribune News Service

Illumina's Singapore Tax Holiday is About to Expire

The DNA sequencing giant generated over 10% of its diluted earnings per share in 2021 from a tax holiday.

The Street

Europe Strikes Down Another Illumina Acquisition

A complicated merger situation for Illumina just got messier.

The Street

Read news from The Economist, FT, and more,
with one subscription

European regulators move to block Illumina's $7.1 billion acquisition of Grail

Europe's antitrust regulator on Tuesday moved to block San Diego's Illumina from acquiring Grail — one week after a U.S. administrative law judge found that the blockbuster $7.1 billion merger should be allowed to stand.

Tribune News Service

$New blood test claims to detect cancer cells before symptoms begin$

New blood test claims to detect cancer cells before symptoms begin

Researchers believe the main cause for surging cancer rates is because humans are living longer. A new test is hoping to detect cancerous cells to allow for earlier treatment for the disease

Daily Mirror

Illumina Stock Pops After European Regulators Block $8 Billion Deal

Illumina stock jumped Tuesday after the EC blocked its acquisition of Grail — another step in a battle over the early cancer-detection outfit.

Investors Business Daily

Top Financial Stories Tuesday, September 6: Focus on iPhone 14 Event, OPEC+ Plans Mild Production Cut, Netflix Says No To Crypto Ads And More…

Reuters EQT Corp Close To Buying THQ Appalachia

Benzinga

Top Financial Stories Friday, September 2: GM's Cruise Recalls Some Robotaxis Over Software Glitch, Chinese Tech Giant Suffers $43M Impairment Loss On Bitcoin and Ethereum Holdings And More..

Wall Street Journal

Benzinga

Tech firms face more regulation after moves to stop 'killer' acquisitions – but innovation could also be under threat

One way to eliminate the competition in business is simply to buy them out and shut them down. And that means less choice for consumers and sometimes the loss of innovative and, in the case of the pharmaceutical industry, even life-saving products. But such so-called killer acquisitions are likely to…

The Conversation

Biden’s FTC has blocked 4 hospital mergers and is poised to thwart more consolidation attempts

Fresh off the Federal Trade Commission’s successful challenges to four hospital mergers, the Biden administration’s new majority on the commission is primed to more aggressively combat consolidation in the health care industry than it has in past years.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Illumina Reports 41% Dip In Q1 Profits Despite 12% Jump in Sales, Reaffirms FY22 Guidance

Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core Illumina business; GRAIL, Illumina's cancer liquid biopsy subsidiary, recorded revenues of $10 million. Product revenue for the quarter totaled $1.07 billion, up 12%, and Service and other revenue amounted to…

USA Today Sports Media Group

With Chevron leaving, PGA Tour Champions brings new golf tournament to Palm Springs area

The event will be played on the Dinah Shore Tournament Course at Mission Hills Country Club.

Chicago Sun-Times

Can ‘liquid biopsy’ cancer blood tests live up to promise of saving lives?

Research is under way even as one company touts its blood test to people with no signs of cancer as a way to detect tumors that have no recommended screening method.

The Independent UK

Can cancer blood tests live up to promise of saving lives?

A new type of blood test that checks for signs of cancer in healthy people has hit the market

Get all your
news in one place.

100’s of premium titles.
One news app.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.